Bellicum Pharmaceuticals’ (BLCM) drug BPX-501 is described as a safe and effective product that can offer children with cancer and other serious diseases the opportunity to beat their intractable sicknesses. The drug enables the patients who are in desperate need for a bone marrow stem cell transplant to use unmatched donors’ stem cells through lowering their adverse effects.
The most recent clinical trial results with BPX-501 were presented in the Presidential Symposium at the 22nd Congress of the European Hematology Association (EHA) being held in Madrid, Spain. The EHA’s . . .